The plasma concentrations of SPON2 in the prostate cancer patients (n = 7, p = 0.634) and benign prostatic hyperplasia patients (n = 6, p = 0.125) tested here had no significant differences comparing with that of the healthy donors. Here, SPON2 is linked to prostate carcinoma.